Internal Medicine, Hematology & Oncology · Houston, TX
NPI
1558624239
Since 2012
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
925 Gessner Rd, Suite 600
Houston, TX, 77024
Phone (713) 827-9525
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
72,819 services
Medicare patients, 2024
213
Average age 74
Drug cost, 2024
$5.9M
1,455 prescriptions
Company payments, 2025
$2,560
From 41 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mona Lisa Alattar was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 13,770 times for 13 patients. In total Mona Lisa Alattar billed 72,819 services in 111 codes, and Medicare paid $1.3M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-03-18.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 13,770 | 13 | $0.28 | $3,855 |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 1,800 | 13 | $0.10 | $186 |
| 85025 Blood Count | Office | 634 | 181 | $7.54 | $4,778 |
| 99214 Office E&M - Established | Office | 334 | 134 | $92.28 | $31K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 244 | 137 | $13.00 | $3,173 |
| 96413 Chemotherapy Administration | Office | 138 | 18 | $101.18 | $14K |
| 96372 Injection Administration | Office | 128 | 22 | $10.92 | $1,398 |
| 99213 Office E&M - Established | Office | 92 | 75 | $66.96 | $6,160 |
| 80047 Clinical Chemistry | Office | 89 | 45 | $13.33 | $1,187 |
| 96367 Intravenous Infusion, Hydration | Office | 78 | 12 | $21.98 | $1,714 |
| 99204 Office E&M - New | Office | 73 | 73 | $114.65 | $8,370 |
| A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 30 | 25 | $104.11 | $3,123 |
| 96365 Intravenous Infusion, Hydration | Office | 29 | 15 | $48.99 | $1,421 |
| 78815 PET- Oncology | Office | 29 | 24 | $1,231.40 | $36K |
| 99215 Office E&M - Established | Office | 26 | 21 | $141.55 | $3,680 |
By year: 2022 $561K for 38,001 services; 2023 $1.1M for 73,751 services; 2024 $1.3M for 72,819 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 634 | 181 | $7.54 | $4,778 |
| 80047 Clinical Chemistry | 89 | 45 | $13.33 | $1,187 |
| 36415 Venipuncture Blood Collection | 21 | 21 | $8.65 | $182 |
Medicare prescription drug claims, 2024
In 2024, the drug Mona Lisa Alattar prescribed most often to Medicare patients was Letrozole, with 84 prescriptions and refills. In total Mona Lisa Alattar wrote 1,455 Medicare prescriptions that cost $5.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 84 | 206 | 34 | $2,099 |
| Famciclovir Generic | 73 | 113 | 21 | $4,552 |
| Anastrozole Generic | 69 | 188 | 32 | $1,408 |
| Exemestane Generic | 63 | 159 | 23 | $10K |
| Dexamethasone Generic | 55 | 59 | 23 | $1,106 |
| Ondansetron Odt Ondansetron | 47 | 47 | 42 | $1,000 |
| Verzenio Abemaciclib | 45 | 46 | 12 | $683K |
| Xarelto Rivaroxaban | 45 | 71 | 12 | $40K |
| Diphenhydramine Hcl Generic | 44 | 44 | Under 11 | $5,744 |
| Calquence Acalabrutinib Maleate | 35 | 35 | Under 11 | $456K |
| Promethazine Hcl Generic | 34 | 34 | Under 11 | $2,067 |
| Hydroxyurea Generic | 32 | 63 | 11 | $735 |
| Revlimid Lenalidomide | 32 | 32 | Under 11 | $571K |
| Granisetron Hcl Generic | 30 | 30 | 28 | $6,414 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 29 | 29 | 28 | $297 |
Brand drugs: 395 claims; generic drugs: 1,060 claims; opioid claims: 47.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mona Lisa Alattar $2,560 ($2,560 in general payments such as food, travel and fees) from 41 companies. The largest payer was Novartis Pharmaceuticals Corporation with $457.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 18 | $457 |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $195 |
| Merck Sharp & Dohme LLC MRK | 7 | $184 |
| Sobi, Inc SOBI.ST | 6 | $181 |
| E.R. Squibb & Sons, L.L.C. BMY | 8 | $163 |
| Kite Pharma, Inc. GILD | 5 | $155 |
| GlaxoSmithKline, LLC. GSK | 4 | $94.28 |
| Puma Biotechnology, Inc. PBYI | 4 | $70.03 |
| Pfizer Inc. PFE | 3 | $66.6 |
| Abbvie Inc. ABBV | 3 | $65.69 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.